Kaya Ltd Share Price

Overview

Kaya Ltd share price is currently ₹357.92, down by - ₹20.84 (5.5%) from its previous closing price of ₹378.76. The share price has gained 28.61% over the past month and declined -15.32% over the past year. The stock's 52-week low and high are ₹220.24 and ₹479.46, respectively. Kaya Ltd has a market capitalisation of ₹ 580.00 Cr. The share price was last updated on 24 Aug 2026, 03:29 PM IST.

Kaya Ltd

KAYA

₹0.00

- ₹20.84

5.50%

Healthcare

₹0.00(%)1D

Updated: 24 Aug 2026, 03:29:56 pm IST

Market Data

Open Price

₹362.66

Prev. Close

₹378.76

₹354.51

Day Low

₹373.01

Day High

₹220.24

52 Week Low

₹479.46

52 Week High

HealthcareHospital & Healthcare Services

CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

-5.59

Sector PE

42.03

PB Ratio

-3.45

Sector PB

5.82

EPS

-64.03

Dividend Yield

0.00

Today's Volume

72.283 K

5 Day Avg. Volume

104.788 K

PEG Ratio

0.03

Market Cap.

₹ 580.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Kaya Ltd 👋

Kaya Limited is an India-based company, which offers skin and hair care solutions using scientific dermatological procedures and products. The Company also sells skin and hair care products through stores, online and third-party outlets. It operates through the Skin Care and Hair Care Business segment. Its services include laser hair reduction, acne scar treatment, anti-ageing, beauty-facial, hair loss treatment, skin-brightening treatment, HydraFacial, Prp treatment, CoolSculpting, chemical peel, facials, and Ultracel Hifu others. Its products include face wash, face cleansers, wipes, toners, moisturizers and creams, serum, hair care, and body care. Its services also include Geolysis, an advanced service for double chin reduction; Sunekos; Liftera HIFU; Hair Wave; Qswitch; Natural Detoxifying Luxury Facial; Black Peel Treatment; Plasma Lift, and others. Its portfolio includes advanced treatments, such as platelet-rich plasma (PRP) therapy and growth factor concentrate (GFC) PRP.